Puma Biotechnology Number Of Shares Shorted vs. Price To Earning
| PBYI Stock | USD 6.09 0.02 0.33% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.86 | 0.7453 |
|
|
This section tracks how Puma Biotechnology profitability aligns with revenue trends, asset use, and equity returns.
Puma Biotechnology's Segment Revenue Breakdown
Puma Biotechnology's revenue is distributed across 2 distinct product categories. Puma Biotechnology's revenue is anchored by Product (59.88 Million, 79.4%), followed by Royalty (15.57 Million, 20.6%). A single segment driving over 60% of revenue suggests limited product diversification, which can amplify both upside and downside.
Your Equity Center.
Macro event markers
Revenue Breakdown by Earning Segment for Puma Biotechnology Details
Puma Biotechnology's product-level revenue split is shown below, highlighting each segment's share of total revenue. At 20.6%, Royalty is the narrowest segment in Puma Biotechnology's product mix.
These estimates offer context for valuation and trend interpretation. They are presented as informational inputs alongside other fundamentals and timeframes.
Quarterly Earnings Growth -0.34 | Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
Market capitalization and book value offer complementary views of Puma Biotechnology - the first driven by investor sentiment, the second by accounting standards. Puma Biotechnology's market capitalization is 308.82 M. A P/B ratio of 2.37 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 239.84 M. Value and price for Puma Biotechnology are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.37, a profit margin of 13.62%, and ROE of 27.97%. The actual Puma Biotechnology transaction price is determined by real-time order flow on the exchange.
Puma Biotechnology Price To Earning vs. Number Of Shares Shorted Fundamental Analysis
Sector-based pricing multiples position Puma Biotechnology within its competitive valuation range. Puma Biotechnology is rated below average for number of shares shorted among direct rivals. It places second for price to earning among direct rivals . Number Of Shares Shorted outpaces Price To Earning by 203,250 times for Puma Biotechnology. Valuation multiples such as P/E, P/B, and P/S compare Puma Biotechnology to peer earnings performance.Puma Price To Earning vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Puma Biotechnology |
| = | 3.76 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Puma Biotechnology |
| = | 18.52 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Puma Price To Earning Comparison
Puma Biotechnology is currently under evaluation for price to earning among direct rivals.
Puma Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Puma Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Puma Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Puma Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Puma Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 36 K | 37.8 K | |
| Operating Income | 37.3 M | 39.2 M | |
| Income Before Tax | 35.8 M | 37.6 M | |
| Net Income | 31.1 M | 32.7 M | |
| Net Income From Continuing Ops | 31.1 M | 32.7 M | |
| Non Operating Income Net Other | -10.5 M | -10 M | |
| Total Other Income Expense Net | -1.5 M | -1.6 M | |
| Net Income Applicable To Common Shares | 2.3 K | 2.4 K | |
| Income Tax Expense | 4.7 M | 4.9 M | |
| Net Interest Income | -2.5 M | -2.7 M | |
| Interest Income | 4.1 M | 2.1 M | |
| Change To Netincome | 21.7 M | 20.6 M | |
| Net Income Per Share | 0.62 | 0.65 | |
| Income Quality | 1.34 | 1.41 | |
| Net Income Per E B T | 0.87 | 0.70 |
Puma Profitability Driver Comparison
Profitability drivers are factors that directly affect the investment outlook for Puma Biotechnology. Investors recognize that outcomes may not unfold as predicted, because unforeseen events and market disruptions can arise at any point and significantly alter the earnings trajectory.
Earnings Estimation Breakdown
The calculation of Puma Biotechnology's earnings per share is based on data from the past 12 consecutive months used for reporting the company's financial figures. The next projected EPS of Puma Biotechnology is estimated to be 0.07 with the future projection ranging from a low of 0.07 to a high of 0.07. Please be aware that this consensus of annual earnings estimates for Puma Biotechnology is based on EPS before non-recurring items.Last Reported EPS
0.07 Lowest | Expected EPS | 0.07 Highest |
Earnings Projection Consensus
A consensus EPS-based estimate above Puma Biotechnology's current price may suggest the market is pricing in excessive pessimism or overlooking near-term catalysts. Conversely, an estimate below market price could reflect a premium valuation that requires sustained earnings growth to justify. Both interpretations demand risk assessment and should not be acted upon in isolation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 1 | 45.4% | 0.0 | 0.07 | 0.63 |
Earnings per Share Projection vs Actual
When Puma Biotechnology reports actual EPS, investors compare it against the analyst consensus estimate for Puma Biotechnology to judge performance. A beat versus consensus is typically interpreted as positive execution; a miss signals a shortfall relative to expectations. EPS is expressed on a weighted average per-share basis to account for equity changes within the reporting period.Estimated Months Earnings per Share
EPS serves income investors in Puma Biotechnology as a quick gauge of dividend affordability: the higher the EPS relative to the dividend per share, the more cushion management has. However, accounting EPS can diverge from cash-based earnings, so investors should validate EPS signals with operating cash flow and capex data. Comparing Puma Biotechnology's EPS to sector peers provides further context for dividend sustainability.Quarterly Analyst Estimates and Surprise Metrics
Earnings surprise history for Puma Biotechnology's reveals whether the company tends to guide conservatively or struggles to meet analyst expectations. A pattern of consistent beats signals strong management execution; repeated misses may indicate structural challenges. Analyst EPS estimates are formed from a combination of forward guidance, sector trends, and macroeconomic inputs.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-26 | 2025-12-31 | 0.27 | 0.29 | 0.02 | 7 | ||
2025-11-06 | 2025-09-30 | 0.16 | 0.21 | 0.05 | 31 | ||
2025-08-07 | 2025-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2025-04-30 | 2025-03-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2025-02-26 | 2024-12-31 | 0.14 | 0.43 | 0.29 | 207 | ||
2024-11-07 | 2024-09-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2024-08-01 | 2024-06-30 | -0.13 | -0.09 | 0.04 | 30 | ||
2024-05-02 | 2024-03-31 | -0.22 | -0.1 | 0.12 | 54 | ||
2024-02-29 | 2023-12-31 | 0.3 | 0.26 | -0.04 | 13 | ||
2023-11-02 | 2023-09-30 | 0.08 | 0.12 | 0.04 | 50 | ||
2023-08-03 | 2023-06-30 | 0.01 | 0.05 | 0.04 | 400 | ||
2023-05-04 | 2023-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2023-03-02 | 2022-12-31 | 0.01 | -0.12 | -0.13 | 1300 | ||
2022-11-03 | 2022-09-30 | -0.05 | -0.01 | 0.04 | 80 | ||
2022-08-04 | 2022-06-30 | 0.0102 | 0.21 | 0.1998 | 1958 | ||
2022-05-05 | 2022-03-31 | -0.17 | -0.08 | 0.09 | 52 | ||
2022-03-03 | 2021-12-31 | -0.09 | 0.1 | 0.19 | 211 | ||
2021-11-04 | 2021-09-30 | -0.31 | -0.9 | -0.59 | 190 | ||
2021-08-05 | 2021-06-30 | -0.27 | -0.13 | 0.14 | 51 | ||
2021-05-06 | 2021-03-31 | 0.09 | 0.4 | 0.31 | 344 | ||
2021-02-25 | 2020-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.79 | -0.4 | 102 | ||
2020-08-06 | 2020-06-30 | -0.3 | 0.08 | 0.38 | 126 | ||
2020-05-07 | 2020-03-31 | -0.77 | -0.43 | 0.34 | 44 | ||
2020-02-20 | 2019-12-31 | -0.48 | -0.29 | 0.19 | 39 | ||
2019-11-06 | 2019-09-30 | -0.71 | -0.44 | 0.27 | 38 | ||
2019-08-08 | 2019-06-30 | -0.95 | -0.97 | -0.02 | 2 | ||
2019-05-09 | 2019-03-31 | -0.68 | -0.26 | 0.42 | 61 | ||
2019-02-28 | 2018-12-31 | -0.77 | -0.8 | -0.03 | 3 | ||
2018-11-01 | 2018-09-30 | -0.97 | -0.37 | 0.6 | 61 | ||
2018-08-09 | 2018-06-30 | -1.26 | -1.17 | 0.09 | 7 | ||
2018-05-09 | 2018-03-31 | -1 | -0.65 | 0.35 | 35 | ||
2018-03-01 | 2017-12-31 | -1.97 | -1.71 | 0.26 | 13 | ||
2017-11-09 | 2017-09-30 | -2.58 | -2.07 | 0.51 | 19 | ||
2017-08-09 | 2017-06-30 | -2.04 | -2.1 | -0.06 | 2 | ||
2017-05-10 | 2017-03-31 | -1.98 | -1.97 | 0.01 | 0 | ||
2017-03-01 | 2016-12-31 | -1.92 | -2.04 | -0.12 | 6 | ||
2016-11-09 | 2016-09-30 | -1.96 | -2.02 | -0.06 | 3 | ||
2016-08-09 | 2016-06-30 | -2.18 | -2.05 | 0.13 | 5 | ||
2016-05-10 | 2016-03-31 | -1.99 | -2.19 | -0.2 | 10 | ||
2016-02-29 | 2015-12-31 | -1.95 | -1.9 | 0.05 | 2 | ||
2015-11-09 | 2015-09-30 | -1.84 | -1.87 | -0.03 | 1 | ||
2015-08-10 | 2015-06-30 | -1.55 | -2.01 | -0.46 | 29 | ||
2015-05-11 | 2015-03-31 | -1.35 | -1.66 | -0.31 | 22 | ||
2015-03-02 | 2014-12-31 | -1.19 | -1.57 | -0.38 | 31 | ||
2014-11-10 | 2014-09-30 | -1.21 | -1.19 | 0.02 | 1 | ||
2014-08-11 | 2014-06-30 | -0.66 | -1.29 | -0.63 | 95 | ||
2014-05-12 | 2014-03-31 | -0.48 | -0.67 | -0.19 | 39 | ||
2014-03-03 | 2013-12-31 | -0.49 | -0.56 | -0.07 | 14 | ||
2013-11-12 | 2013-09-30 | -0.46 | -0.5 | -0.04 | 8 | ||
2013-08-06 | 2013-06-30 | -0.43 | -0.44 | -0.01 | 2 | ||
2013-05-09 | 2013-03-31 | -0.63 | -0.41 | 0.22 | 34 | ||
2013-03-31 | 2012-12-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2012-11-14 | 2012-09-30 | -0.52 | -1.29 | -0.77 | 148 | ||
2012-08-14 | 2012-06-30 | -0.35 | -0.22 | 0.13 | 37 | ||
2012-05-15 | 2012-03-31 | -0.25 | -0.57 | -0.32 | 128 |
Use Puma Biotechnology in pair-trading
Pair trading with Puma Biotechnology can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Puma Biotechnology Pair Trading
Puma Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Puma Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Puma Biotechnology when you sell it.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.
Correlation analysis and pair evaluation for Puma Biotechnology can support hedging context. This approach is commonly reviewed within sectors and across broader groups.Use Investing Themes to Complement your Puma Biotechnology position
With 308.82 Million market cap in the Biotechnology industry, Puma Biotechnology works well as a smaller-cap core holding around which broader thematic baskets can be built. Anchoring a Biotechnology theme around Puma Biotechnology at 308.82 Million can be tuned for upside participation or tighter downside control depending on Healthcare outlook.
Did You Try This Idea?
Run Broad Municipals ETFs Thematic Idea Now
Broad Municipals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Municipals ETFs theme has 57 constituents at this time.
Explore the Broad Municipals ETFs Theme as a thematic allocation that can be optimized for return targets or risk constraints.
| View All Next | Launch |
More Resources for Puma Stock Analysis
Reviewing Puma Biotechnology commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Puma Biotechnology's operating context across reporting periods. Key reports that frame Puma Biotechnology Stock are listed below:Your Equity Center. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Puma Biotechnology P/E of 18.52 alongside ROE at 27.97% frames the starting point - the resources below add portfolio-level context that single-security analysis cannot provide alone. That valuation within Healthcare invites comparison with Biotechnology peers using the tools below to judge whether the multiple is justified. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Projecting Puma Biotechnology's profitability starts with historical financial statements. The core view includes income statement, balance sheet, and cash flow.